Inlexzo gets the nod in BCG-unresponsive non-muscle invasive bladder cancer, but the group has bigger plans.

But the company is awaiting pivotal results with TAR-200 in papillary disease before filing.

The company’s TARA-002 produces competitive results in BCG-unresponsive bladder cancer, albeit in just five patients.

The first approval for TAR-200 is on the horizon, setting up a challenge to Keytruda.

After Niagara the company faces three pivotal catalysts; none is a slam-dunk.

A royalty financing deal should see this gene therapy launched nine months after its surprise US approval.